Clinical Observation on Modified Sheganmahuang Tang Plus Symbicort in Treating the Acute Attack of Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome

OBJECTIVE To observe the clinical effect of modified Sheganmahuang Tang plus symbicort in treating the acute attack of asthma-chronic obstructive pulmonary disease overlap syndrome(ACOS). METHODS Forty-two ACOS patients were divided into the experimental group (22 cases) and the control group (20 cases) according to the random number. On the basis of conventional western drug symptomatic treatment including oxygen inhalation， stopping cough and resolving phlegm， bronchus dilation， anti-infection， the control group was given symbicort inhalation， and the experimental group was given Sheganmahuang Tang plus symbicort. The treatment course was 4 weeks. the curative effects of both groups were observed. RESULTS In terms of clinical effect， the totally effective rates of the experimental group and the control group were 96.00% and 65.00%， respectively， and the difference between two groups was significant， P<0.05. The FEV1% and FEV1/FVC increased significantly compared with the control group， P<0.05. DLCO in the experimental group increased slightly higher than that in the control group， P>0.05; CAT score (16±2) decreased significantly compared with the control group (20±2); and the ACT score (24±3) increased significantly compared with the control group (16±2)， P<0.05. The reoccurrence rate in the experimental group decreased significantly compared with the control group， P<0.05~0.01. Both groups reported no severe adverse event. CONCLUSION Sheganmahuang Tang plus symbicort achieves satisfactory curative effect in the treatment of acute attack of ACOS with no severe adverse event， which is worthy of spreading.